开云app官网登录入口网页版-官方正版

#REM#

111篇内容 | 2137人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1752319, encodeId=00e51e52319bb, content=<a href='/topic/show?id=28a915303ec' target=_blank style='color:#2F92EE;'>#REM#</a>, objectTitle=Rheumatology：Apremilast单药治疗DMARD无效的活动性银屑病关节炎的长期疗效, objectType=article, longId=301742, objectId=ea63301e42f2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ea63301e42f2, replyNumber=0, likeNumber=73, createdTime=2022-04-30, rootId=0, userName=tongyongming, userId=78bc36479935, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ea63301e42f2, moduleTitle=Rheumatology：Apremilast单药治疗DMARD无效的活动性银屑病关节炎的长期疗效, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=ea63301e42f2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1752321, encodeId=01491e52321e9, content=<a href='/topic/show?id=28a915303ec' target=_blank style='color:#2F92EE;'>#REM#</a>, objectTitle=NEJM Evid：Tremelimumab联合Durvalumab用于不可切除肝细胞癌的治疗, objectType=article, longId=729494, objectId=1842e294948c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1842e294948c, replyNumber=0, likeNumber=78, createdTime=2023-01-30, rootId=0, userName=tongyongming, userId=78bc36479935, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1842e294948c, moduleTitle=NEJM Evid：Tremelimumab联合Durvalumab用于不可切除肝细胞癌的治疗, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=1842e294948c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1752315, encodeId=71e31e52315de, content=<a href='/topic/show?id=28a915303ec' target=_blank style='color:#2F92EE;'>#REM#</a>, objectTitle=Mov Disord.:7T磁共振发现REM期睡眠行为障碍患者脑干核间结构连接受损, objectType=article, longId=293434, objectId=b4c82934343b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b4c82934343b, replyNumber=0, likeNumber=77, createdTime=2022-09-02, rootId=0, userName=tongyongming, userId=78bc36479935, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b4c82934343b, moduleTitle=Mov Disord.:7T磁共振发现REM期睡眠行为障碍患者脑干核间结构连接受损, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=b4c82934343b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1752322, encodeId=53e91e523226b, content=<a href='/topic/show?id=28a915303ec' target=_blank style='color:#2F92EE;'>#REM#</a>, objectTitle=AOP Health在2022年欧洲血液学协会年会上公布CONTINUATION-PV研究的最终结果——BESREMi®（罗培根干扰素α-2b）治疗真性红细胞增多症患者长达7.5年, objectType=article, longId=730162, objectId=903de30162e2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=903de30162e2, replyNumber=0, likeNumber=80, createdTime=2023-04-02, rootId=0, userName=tongyongming, userId=78bc36479935, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=903de30162e2, moduleTitle=AOP Health在2022年欧洲血液学协会年会上公布CONTINUATION-PV研究的最终结果——BESREMi®（罗培根干扰素α-2b）治疗真性红细胞增多症患者长达7.5年, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=903de30162e2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1752314, encodeId=a7d21e523147e, content=<a href='/topic/show?id=28a915303ec' target=_blank style='color:#2F92EE;'>#REM#</a>, objectTitle=NEJM:加拿大解除米非司酮REMS限制对流产安全的影响, objectType=article, longId=260124, objectId=b21126012424, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b21126012424, replyNumber=0, likeNumber=77, createdTime=2022-05-20, rootId=0, userName=tongyongming, userId=78bc36479935, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b21126012424, moduleTitle=NEJM:加拿大解除米非司酮REMS限制对流产安全的影响, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=b21126012424)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1752320, encodeId=53821e523201c, content=<a href='/topic/show?id=28a915303ec' target=_blank style='color:#2F92EE;'>#REM#</a>, objectTitle=Nature Cancer：仁济医院高维强教授发现Gremlin1可能是去势抵抗性前列腺癌治疗新靶点, objectType=article, longId=728547, objectId=db53e28547ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=db53e28547ba, replyNumber=0, likeNumber=126, createdTime=2022-08-07, rootId=0, userName=tongyongming, userId=78bc36479935, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=db53e28547ba, moduleTitle=Nature Cancer：仁济医院高维强教授发现Gremlin1可能是去势抵抗性前列腺癌治疗新靶点, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=db53e28547ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1752316, encodeId=a91a1e523167d, content=<a href='/topic/show?id=28a915303ec' target=_blank style='color:#2F92EE;'>#REM#</a>, objectTitle=Imfinzi联合tremelimumab在肝癌中显示出延长OS的益处, objectType=article, longId=294612, objectId=c7ac294612ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c7ac294612ce, replyNumber=0, likeNumber=78, createdTime=2022-12-07, rootId=0, userName=tongyongming, userId=78bc36479935, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c7ac294612ce, moduleTitle=Imfinzi联合tremelimumab在肝癌中显示出延长OS的益处, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=c7ac294612ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1752312, encodeId=62491e52312e2, content=<a href='/topic/show?id=28a915303ec' target=_blank style='color:#2F92EE;'>#REM#</a>, objectTitle=美国FDA核准BESREMi® (Ropeginterferon α-2b), objectType=article, longId=220622, objectId=7e4422062262, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7e4422062262, replyNumber=0, likeNumber=77, createdTime=2022-03-19, rootId=0, userName=tongyongming, userId=78bc36479935, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7e4422062262, moduleTitle=美国FDA核准BESREMi® (Ropeginterferon α-2b), moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=7e4422062262)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1752317, encodeId=9c541e5231786, content=<a href='/topic/show?id=28a915303ec' target=_blank style='color:#2F92EE;'>#REM#</a>, objectTitle=REMD：多囊卵巢综合征与新冠肺炎感染风险的研究, objectType=article, longId=300093, objectId=bb6a3000934a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bb6a3000934a, replyNumber=0, likeNumber=72, createdTime=2023-02-14, rootId=0, userName=tongyongming, userId=78bc36479935, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bb6a3000934a, moduleTitle=REMD：多囊卵巢综合征与新冠肺炎感染风险的研究, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=bb6a3000934a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1752308, encodeId=a7511e52308a8, content=<a href='/topic/show?id=28a915303ec' target=_blank style='color:#2F92EE;'>#REM#</a>, objectTitle=Clin Cancer Res：HDAC抑制剂Remetinostat凝胶用于基底细胞癌的治疗活性, objectType=article, longId=216890, objectId=3239216890aa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3239216890aa, replyNumber=0, likeNumber=77, createdTime=2022-05-07, rootId=0, userName=tongyongming, userId=78bc36479935, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3239216890aa, moduleTitle=Clin Cancer Res：HDAC抑制剂Remetinostat凝胶用于基底细胞癌的治疗活性, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=3239216890aa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1752307, encodeId=ef1c1e523079f, content=<a href='/topic/show?id=28a915303ec' target=_blank style='color:#2F92EE;'>#REM#</a>, objectTitle=Nat Commun：小檗碱和益生菌对2型糖尿病肠道微生物的影响——PREMOTE研究, objectType=article, longId=215114, objectId=f26321511411, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f26321511411, replyNumber=0, likeNumber=96, createdTime=2021-10-19, rootId=0, userName=tongyongming, userId=78bc36479935, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f26321511411, moduleTitle=Nat Commun：小檗碱和益生菌对2型糖尿病肠道微生物的影响——PREMOTE研究, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=f26321511411)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1752318, encodeId=d6151e5231819, content=<a href='/topic/show?id=28a915303ec' target=_blank style='color:#2F92EE;'>#REM#</a>, objectTitle=Lancet Neurol：可溶性TREM2与常染色体显性遗传阿尔茨海默病其他标志物及认知功能的相关性, objectType=article, longId=301291, objectId=5d4330129115, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5d4330129115, replyNumber=0, likeNumber=63, createdTime=2022-10-28, rootId=0, userName=tongyongming, userId=78bc36479935, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5d4330129115, moduleTitle=Lancet Neurol：可溶性TREM2与常染色体显性遗传阿尔茨海默病其他标志物及认知功能的相关性, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=5d4330129115)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1752304, encodeId=c9f71e523042b, content=<a href='/topic/show?id=28a915303ec' target=_blank style='color:#2F92EE;'>#REM#</a>, objectTitle=Acta Neuropathologica: 朊病毒疾病中TREM2在脑和生物体液中的表达, objectType=article, longId=211431, objectId=e71a21143137, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e71a21143137, replyNumber=0, likeNumber=67, createdTime=2021-12-25, rootId=0, userName=tongyongming, userId=78bc36479935, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e71a21143137, moduleTitle=Acta Neuropathologica: 朊病毒疾病中TREM2在脑和生物体液中的表达, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=e71a21143137)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1752305, encodeId=dd8f1e5230558, content=<a href='/topic/show?id=28a915303ec' target=_blank style='color:#2F92EE;'>#REM#</a>, objectTitle=Circulation：新型愈合导向药物洗脱支架Supreme DES用于急慢性冠脉综合征患者的疗效和安全性, objectType=article, longId=212279, objectId=b9c52122e99b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b9c52122e99b, replyNumber=0, likeNumber=65, createdTime=2022-05-09, rootId=0, userName=tongyongming, userId=78bc36479935, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b9c52122e99b, moduleTitle=Circulation：新型愈合导向药物洗脱支架Supreme DES用于急慢性冠脉综合征患者的疗效和安全性, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=b9c52122e99b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1752310, encodeId=0d731e5231052, content=<a href='/topic/show?id=28a915303ec' target=_blank style='color:#2F92EE;'>#REM#</a>, objectTitle=Front Oncol：每周PCC方案（紫杉醇+卡铂+西妥昔单抗）可用于不适合EXTREME方案治疗复发和/或转移性头颈部鳞状细胞癌（R/M-HNSCC）患者, objectType=article, longId=219629, objectId=09d321962921, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=09d321962921, replyNumber=0, likeNumber=85, createdTime=2022-09-07, rootId=0, userName=tongyongming, userId=78bc36479935, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=09d321962921, moduleTitle=Front Oncol：每周PCC方案（紫杉醇+卡铂+西妥昔单抗）可用于不适合EXTREME方案治疗复发和/或转移性头颈部鳞状细胞癌（R/M-HNSCC）患者, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=09d321962921)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1752309, encodeId=2f661e52309b3, content=<a href='/topic/show?id=28a915303ec' target=_blank style='color:#2F92EE;'>#REM#</a>, objectTitle=Imfinzi联合tremelimumab治疗肝癌，III期试验显示可提高总体生存率, objectType=article, longId=218686, objectId=4c14218686ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4c14218686ce, replyNumber=0, likeNumber=60, createdTime=2022-09-14, rootId=0, userName=tongyongming, userId=78bc36479935, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4c14218686ce, moduleTitle=Imfinzi联合tremelimumab治疗肝癌，III期试验显示可提高总体生存率, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=4c14218686ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1752313, encodeId=a0b31e5231341, content=<a href='/topic/show?id=28a915303ec' target=_blank style='color:#2F92EE;'>#REM#</a>, objectTitle=J Thorac Oncol：Durvalumab +tremelimumab联合或不联合化疗一线治疗驱动基因阴性的转移性NSCLC患者的疗效和安全性, objectType=article, longId=220795, objectId=abf7220e9596, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=abf7220e9596, replyNumber=0, likeNumber=62, createdTime=2022-04-28, rootId=0, userName=tongyongming, userId=78bc36479935, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=abf7220e9596, moduleTitle=J Thorac Oncol：Durvalumab +tremelimumab联合或不联合化疗一线治疗驱动基因阴性的转移性NSCLC患者的疗效和安全性, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=abf7220e9596)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1752306, encodeId=6f381e523062d, content=<a href='/topic/show?id=28a915303ec' target=_blank style='color:#2F92EE;'>#REM#</a>, objectTitle=J Clin Oncol：Tremelimumab 联合Durvalumab治疗不可切除肝细胞癌安全性和疗效：随机I/II期研究, objectType=article, longId=214768, objectId=1da3214e68e5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1da3214e68e5, replyNumber=0, likeNumber=85, createdTime=2022-03-01, rootId=0, userName=tongyongming, userId=78bc36479935, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1da3214e68e5, moduleTitle=J Clin Oncol：Tremelimumab 联合Durvalumab治疗不可切除肝细胞癌安全性和疗效：随机I/II期研究, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=1da3214e68e5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1752311, encodeId=a8371e5231189, content=<a href='/topic/show?id=28a915303ec' target=_blank style='color:#2F92EE;'>#REM#</a>, objectTitle=JNNP:抑郁症患者REM睡眠行为障碍的患病率及其相关因素, objectType=article, longId=220305, objectId=ca1d220305e9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ca1d220305e9, replyNumber=0, likeNumber=95, createdTime=2022-02-01, rootId=0, userName=tongyongming, userId=78bc36479935, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ca1d220305e9, moduleTitle=JNNP:抑郁症患者REM睡眠行为障碍的患病率及其相关因素, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=ca1d220305e9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1752300, encodeId=ab291e52300d6, content=<a href='/topic/show?id=28a915303ec' target=_blank style='color:#2F92EE;'>#REM#</a>, objectTitle=JNNP：突触核蛋白病作为原发性REM睡眠行为障碍的病理生物标志物, objectType=article, longId=203812, objectId=3db620381245, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3db620381245, replyNumber=0, likeNumber=77, createdTime=2021-08-02, rootId=0, userName=tongyongming, userId=78bc36479935, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3db620381245, moduleTitle=JNNP：突触核蛋白病作为原发性REM睡眠行为障碍的病理生物标志物, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=3db620381245)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

REM

2020-05-29

tongyongming (审核中...)

前往app查看评论内容

#REM#

Rheumatology：Apremilast单药治疗DMARD无效的活动性银屑病关节炎的长期疗效

2022-04-30

tongyongming (审核中...)

前往app查看评论内容

#REM#

NEJM Evid：Tremelimumab联合Durvalumab用于不可切除肝细胞癌的治疗

2023-01-30

tongyongming (审核中...)

前往app查看评论内容

#REM#

Mov Disord.:7T磁共振发现REM期睡眠行为障碍患者脑干核间结构连接受损

2022-09-02

tongyongming (审核中...)

前往app查看评论内容

#REM#

AOP Health在2022年欧洲血液学协会年会上公布CONTINUATION-PV研究的最终结果——BESREMi®（罗培根干扰素α-2b）治疗真性红细胞增多症患者长达7.5年

2023-04-02

tongyongming (审核中...)

前往app查看评论内容

#REM#

NEJM:加拿大解除米非司酮REMS限制对流产安全的影响

2022-05-20

tongyongming (审核中...)

前往app查看评论内容

#REM#

Nature Cancer：仁济医院高维强教授发现Gremlin1可能是去势抵抗性前列腺癌治疗新靶点

2022-08-07

tongyongming (审核中...)

前往app查看评论内容

#REM#

Imfinzi联合tremelimumab在肝癌中显示出延长OS的益处

2022-12-07

tongyongming (审核中...)

前往app查看评论内容

#REM#

美国FDA核准BESREMi® (Ropeginterferon α-2b)

2022-03-19

tongyongming (审核中...)

前往app查看评论内容

#REM#

REMD：多囊卵巢综合征与新冠肺炎感染风险的研究

2023-02-14

tongyongming (审核中...)

前往app查看评论内容

#REM#

Clin Cancer Res：HDAC抑制剂Remetinostat凝胶用于基底细胞癌的治疗活性

2022-05-07

tongyongming (审核中...)

前往app查看评论内容

#REM#

Nat Commun：小檗碱和益生菌对2型糖尿病肠道微生物的影响——PREMOTE研究

2021-10-19

tongyongming (审核中...)

前往app查看评论内容

#REM#

Lancet Neurol：可溶性TREM2与常染色体显性遗传阿尔茨海默病其他标志物及认知功能的相关性

2022-10-28

tongyongming (审核中...)

前往app查看评论内容

#REM#

Acta Neuropathologica: 朊病毒疾病中TREM2在脑和生物体液中的表达

2021-12-25

tongyongming (审核中...)

前往app查看评论内容

#REM#

Circulation：新型愈合导向药物洗脱支架Supreme DES用于急慢性冠脉综合征患者的疗效和安全性

2022-05-09

tongyongming (审核中...)

前往app查看评论内容

#REM#

Front Oncol：每周PCC方案（紫杉醇+卡铂+西妥昔单抗）可用于不适合EXTREME方案治疗复发和/或转移性头颈部鳞状细胞癌（R/M-HNSCC）患者

2022-09-07

tongyongming (审核中...)

前往app查看评论内容

#REM#

Imfinzi联合tremelimumab治疗肝癌，III期试验显示可提高总体生存率

2022-09-14

tongyongming (审核中...)

前往app查看评论内容

#REM#

J Thorac Oncol：Durvalumab +tremelimumab联合或不联合化疗一线治疗驱动基因阴性的转移性NSCLC患者的疗效和安全性

2022-04-28

tongyongming (审核中...)

前往app查看评论内容

#REM#

J Clin Oncol：Tremelimumab 联合Durvalumab治疗不可切除肝细胞癌安全性和疗效：随机I/II期研究

2022-03-01

tongyongming (审核中...)

前往app查看评论内容

#REM#

JNNP:抑郁症患者REM睡眠行为障碍的患病率及其相关因素

2022-02-01

tongyongming (审核中...)

前往app查看评论内容

#REM#

JNNP：突触核蛋白病作为原发性REM睡眠行为障碍的病理生物标志物

2021-08-02

科室
- - 订阅+
  - 更多科室
工具
服务